Phenotypic changes in ciprofloxacin-resistant Staphylococcus aureus

Research in Microbiology

Volumn 160, Issue 10, 2009, Pages 785-791

  Mesak, Lili R ^a   Davies, Julian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Efflux pumps; Fluoroquinolone; Major facilitator superfamily (MFS); Resistance; Transcription modulation

Indexed keywords

BACTERIAL PROTEIN; BLEOMYCIN; CIPROFLOXACIN; CONGOCIDINE; DISTAMYCIN A; ETHIDIUM BROMIDE; LEXA PROTEIN; MITOMYCIN C; MOXIFLOXACIN; NALIDIXIC ACID; NORA PROTEIN; NORFLOXACIN; PHLEOMYCIN; RECA PROTEIN; RESERPINE; RIFAMPICIN; SOSA PROTEIN; TRIMETHOPRIM; UMUC PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROMOTER REGION; STAPHYLOCOCCUS AUREUS; TRANSCRIPTION REGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; AZA COMPOUNDS; BACTERIAL PROTEINS; CIPROFLOXACIN; DNA MISMATCH REPAIR; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, BACTERIAL; MITOMYCIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; QUINOLINES; SOS RESPONSE (GENETICS); STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 70849094358     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2009.09.013     Document Type: Article

References (42)

1. Aires de Sousa M., and de Lencastre H. Bridges from hospitals to the laboratory: genetic portraits of methicillin-resistant Staphylococcus aureus clones. FEMS Immunol. Med. Microbiol. 40 (2004) 101-111
2. Antony S.J. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand. J. Infect. Dis. 38 (2006) 293-295
3. Baldoni D., Haschke M., Rajacic Z., Zimmerli W., and Trampuz A. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents Chemother. 53 (2009) 1142-1148
4. Bochner B.R. Global phenotypic characterization of bacteria. FEMS Microbiol. Rev. 33 (2009) 191-205
5. Bochner B.R., Gadzinski P., and Panomitros E. Phenotype microarrays for high-throughput phenotypic testing and assay of gene function. Genome Res. 11 (2001) 1246-1255
6. Cheo D.L., Bayles K.W., and Yasbin R.E. Cloning and characterization of DNA damage-inducible promoter regions from Bacillus subtilis. J. Bacteriol. 173 (1991) 1696-1703
7. Cirz R.T., Jones M.B., Gingles N.A., Minogue T.D., Jarrahi B., Peterson S.N., et al. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J. Bacteriol. 189 (2007) 531-539
8. Couto I., Costa S.S., Viveiros M., Martins M., and Amaral L. Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. J. Antimicrob. Chemother. 62 (2008) 504-513
9. DeMarco C.E., Cushing L.A., Frempong-Manso E., Seo S.M., Jaravaza T.A., and Kaatz G.W. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 51 (2007) 3235-5239
10. Ding Y., Onodera Y., Lee J.C., and Hooper D.C. NorB, an efflux pump in Staphylococcus aureus MW2, contributes to bacterial fitness in abscesses. J. Bacteriol. 190 (2008) 7123-7129
11. Drlica K., and Malik M. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 3 (2003) 249-282
12. Duthie E.S., and Lorenz L.L. Staphylococcal coagulase; mode of action and antigenicity. J. Gen. Microbiol. 6 (1952) 95-107
13. Dworkin R.J., Lee B.L., Sande M.A., and Chambers H.F. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 2 (1989) 1071-1073
14. Dworkin R., Modin G., Kunz S., Rich R., Zak O., and Sande M. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob. Agents Chemother. 34 (1990) 1014-1016
15. Erill I., Campoy S., and Barbe J. Aeons of distress: an evolutionary perspective on the bacterial SOS response. FEMS Microbiol. Rev. 31 (2007) 637-656
16. Fournier B., Aras R., and Hooper D.C. Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system. J. Bacteriol. 182 (2000) 664-671
17. Fournier B., and Hooper D.C. A new two-component regulatory system involved in adhesion, autolysis, and extracellular proteolytic activity of Staphylococcus aureus. J. Bacteriol. 182 (2000) 3955-3964
18. Goh E.B., Yim G., Tsui W., McClure J., Surette M.G., and Davies J. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 17025-17030
19. Hooper D.C. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2 (2002) 530-538
20. Jacoby G.A. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41 Suppl. 2 (2005) S120-126
21. Kaatz G.W., Seo S.M., and Foster T.J. Introduction of a norA promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration. Antimicrob. Agents Chemother. 43 (1999) 2222-2224
22. Kaatz G.W., Seo S.M., and Ruble C.A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37 (1993) 1086-1094
23. Kaatz G.W., Thyagarajan R.V., and Seo S.M. Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter. Antimicrob. Agents Chemother. 49 (2005) 161-169
24. Kreiswirth B.N., Lofdahl S., Betley M.J., O'Reilly M., Schlievert P.M., Bergdoll M.S., et al. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305 (1983) 709-712
25. Mesak L.R., Miao V., and Davies J. Effects of subinhibitory concentrations of antibiotics on SOS and DNA repair gene expression in Staphylococcus aureus. Antimicrob. Agents Chemother. 52 (2008) 3394-3397
26. Mesak L.R., Yim G., and Davies J. Improved lux reporters for use in Staphylococcus aureus. Plasmid 61 (2009) 182-187
27. Murakami K., and Tomasz A. Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus. J. Bacteriol. 171 (1989) 874-879
28. Noguchi N., Okihara T., Namiki Y., Kumaki Y., Yamanaka Y., Koyama M., et al. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int. J. Antimicrob. Agents 25 (2005) 374-379
29. Schenk S., and Laddaga R.A. Improved method for electroporation of Staphylococcus aureus. FEMS Microbiol. Lett. 73 (1992) 133-138
30. Schlacher K., and Goodman M.F. Lessons from 50 years of SOS DNA-damage-induced mutagenesis. Nat. Rev. Mol. Cell Biol. 8 (2007) 587-594
31. Strahilevitz J., and Hooper D.C. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob. Agents Chemother. 49 (2005) 1949-1956
32. Strahilevitz J., Truong-Bolduc Q.C., and Hooper D.C. DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob. Agents Chemother. 49 (2005) 5051-5057
33. Truong-Bolduc Q.C., Dunman P.M., Strahilevitz J., Projan S.J., and Hooper D.C. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J. Bacteriol. 187 (2005) 2395-2405
34. Truong-Bolduc Q.C., Strahilevitz J., and Hooper D.C. NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob. Agents Chemother. 50 (2006) 1104-1107
35. Truong-Bolduc Q.C., Zhang X., and Hooper D.C. Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J. Bacteriol. 185 (2003) 3127-3138
36. Tsui W.H., Yim G., Wang H.H., McClure J.E., Surette M.G., and Davies J. Dual effects of MLS antibiotics: transcriptional modulation and interactions on the ribosome. Chem. Biol. 11 (2004) 1307-1316
37. Vicente M., Hodgson J., Massidda O., Tonjum T., Henriques-Normark B., and Ron E.Z. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time?. FEMS Microbiol. Rev. 30 (2006) 841-852
38. Wise R., Andrews J.M., and Edwards L.J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother. 23 (1983) 559-564
39. Wolfson J.S., and Hooper D.C. Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev. 2 (1989) 378-424
40. Xiao Y., Li Y., Liu J., Zhong W., and Yang W. In vitro antibacterial activity of DX-619, a novel Des-F (6)-quinolone against clinical isolates in China. J. Chemother. 19 (2007) 632-642
41. Yim G., de la Cruz F., Spiegelman G.B., and Davies J. Transcription modulation of Salmonella enterica serovar Typhimurium promoters by sub-MIC levels of rifampin. J. Bacteriol. 188 (2006) 7988-7991
42. Yoshida H., Bogaki M., Nakamura S., Ubukata K., and Konno M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172 (1990) 6942-9694